Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 15/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | DTYMK | P23919 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31088390 | 0.93 | PTGDR2 (0.51) | ENPP2DDB1CRBNHDAC1HDAC6 | |
| SCHEMBL30130265 | 0.91 | ENPP2 (0.51) | ENPP2DDB1CRBNHDAC1HDAC6 | |
| SCHEMBL30130284 | 0.91 | DDB1 (0.51) | ENPP2DDB1CRBNHDAC1HDAC6 | |
| SCHEMBL30130208 | 0.91 | ENPP2 (0.50) | ENPP2DDB1CRBNHDAC1HDAC6 | |
| SCHEMBL30130263 | 0.91 | DDB1 (0.50) | ENPP2DDB1CRBNHDAC1HDAC6 | |
| SCHEMBL30130278 | 0.91 | DDB1 (0.50) | ENPP2DDB1CRBNHDAC1HDAC6 | |
| SCHEMBL24914777 | 0.90 | ENPP2 (0.54) | ENPP2DDB1CRBNHDAC1HDAC6 | |
| SCHEMBL30130231 | 0.90 | DDB1 (0.49) | ENPP2DDB1CRBNHDAC1HDAC6 | |
| SCHEMBL30130247 | 0.89 | P2RX3 (0.49) | ENPP2DDB1CRBNHDAC1HDAC6 | |
| SCHEMBL28984498 | 0.88 | ENPP2 (0.55) | ENPP2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327408-A1 | COMPOUNDS CONTAINING TETRAHYDRONAPHTHYRIDINONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2024-10-03 | — | — | US | disclosed |
| CN-115611896-A | Compound containing tetralone or tetrahydropyridopyrimidone skeleton and preparation method and pharmaceutical application thereof | 中国药科大学 | 2023-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327408-A1 | COMPOUNDS CONTAINING TETRAHYDRONAPHTHYRIDINONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | PRCP, TMPRSS15, WEE1 | ENPP2 1245/4885DDB1 3529/4885CRBN 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.